Literature DB >> 4984420

Rifampicin activity "in vitro" and in established tuberculosis in mice.

L Verbist.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4984420

Source DB:  PubMed          Journal:  Acta Tuberc Pneumol Belg        ISSN： 0001-7078


× No keyword cloud information.
  9 in total

1.  Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Authors:  Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Ming Zhang; Deepak Almeida; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 2.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

3.  Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Charles A Peloquin; Andrew A Vernon; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2006-03-30       Impact factor: 21.405

Review 4.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

5.  Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong.

Authors:  M Aquinas; W G Allan; P A Horsfall; P K Jenkins; W Hung-Yan; D Girling; R Tall; W Fox
Journal:  Br Med J       Date:  1972-03-25

6.  Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Weiguo Liu; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

Review 7.  Understanding pharmacokinetics to improve tuberculosis treatment outcome.

Authors:  Jonathan Reynolds; Scott K Heysell
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-03-06       Impact factor: 4.481

8.  Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.

Authors:  Meredith Milstein; Leonid Lecca; Charles Peloquin; Denis Mitchison; Kwonjune Seung; Marcello Pagano; David Coleman; Elna Osso; Julia Coit; Dante Elmo Vargas Vasquez; Epifanio Sanchez Garavito; Roger Calderon; Carmen Contreras; Geraint Davies; Carole D Mitnick
Journal:  BMC Infect Dis       Date:  2016-08-27       Impact factor: 3.090

9.  Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.

Authors:  Nguyen Thi Ngoc Lan; Nguyen Thi Nguyet Thu; Aurélie Barrail-Tran; Nguyen Hong Duc; Nguyen Ngoc Lan; Didier Laureillard; Truong Thi Xuan Lien; Laurence Borand; Catherine Quillet; Catherine Connolly; Dominique Lagarde; Alexander Pym; Christian Lienhardt; Nguyen Huy Dung; Anne-Marie Taburet; Anthony D Harries
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.